<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00768508</url>
  </required_header>
  <id_info>
    <org_study_id>12790</org_study_id>
    <secondary_id>R01AA012964</secondary_id>
    <nct_id>NCT00768508</nct_id>
  </id_info>
  <brief_title>Combined Pharmacotherapies for Alcoholism</brief_title>
  <official_title>Combined Pharmacotherapies for Alcoholism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bankole Johnson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study would like to test whether the combination of ondansetron and naltrexone will be&#xD;
      superior to either medication alone or placebo in the treatment of alcohol dependence.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We propose to conduct a 13 week randomized, controlled clinical trial to evaluate the safety&#xD;
      and efficacy of ondansetron and naltrexone alone and in combination.Eligible subjects will be&#xD;
      randomized to placebo, ondansetron, naltrexone, or ondansetron + naltrexone treatments. All&#xD;
      subjects will receive a weekly CBT (Cognitive Behavioral Therapy)sessions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Self-report measures of alcohol-related problems and consumption, Objective measures of alcohol consumption</measure>
    <time_frame>Throughout the study</time_frame>
    <description>Drinks per drinking day, Drinks per day, Percent Days Abstinent, BAC, CDT, GGT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Medication compliance, alcohol craving, social functioning, quality of life, alcohol withdrawal, attendance at psychosocial services, pre-morbid risk factors</measure>
    <time_frame>Throughout the study</time_frame>
    <description>Pill Count, SFQ, AASE, ADBS, OCDS, CIWA-Ar, CGI, TCI, MAC, AOQ, FHAM</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Alcoholism</condition>
  <arm_group>
    <arm_group_label>Ondansetron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ondansetron 4 ug/kg b.i.d. + Cognitive Behavioral Therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naltrexone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naltrexone 50 mg/day + Cognitive Behavioral Therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ondansetron + Naltrexone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ondansetron 4 ug/kg b.i.d. + Naltrexone 50 mg/day + Cognitive Behavioral Therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo + Cognitive Behavioral Therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron 4 ug/kg b.i.d. + Cognitive Behavioral Therapy</intervention_name>
    <description>Ondansetron 4 ug/kg b.i.d.for 12 weeks</description>
    <arm_group_label>Ondansetron</arm_group_label>
    <other_name>Zofran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone 50 mg/day + Cognitive Behavioral Therapy</intervention_name>
    <description>Naltrexone 50 mg/day for 12 weeks</description>
    <arm_group_label>Naltrexone</arm_group_label>
    <other_name>Revia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron 4 ug/kg b.i.d.+ Naltrexone 50 mg/day + Cognitive Behavioral Therapy</intervention_name>
    <description>Combination of ondansetron 4 ug/kg b.i.d. and naltrexone 50 mg/day for 12 weeks</description>
    <arm_group_label>Ondansetron + Naltrexone</arm_group_label>
    <other_name>Zofran and Revia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo + Cognitive Behavioral Therapy</intervention_name>
    <description>Placebo comparator</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females who have given written informed consent.&#xD;
&#xD;
          -  Ages 18 years and above and must weigh at least 40 kg and no more than 140 kg.&#xD;
&#xD;
          -  Good physical health as determined by a complete physical examination, an EKG within&#xD;
             normal limits, and laboratory screening tests within acceptable parameters (see&#xD;
             exclusion criteria).&#xD;
&#xD;
          -  Current DSM-IV diagnosis of alcohol dependence&#xD;
&#xD;
          -  AUDIT score of equal or more than 8.&#xD;
&#xD;
          -  Currently drinking&#xD;
&#xD;
          -  Provide evidence of stable residence in the last month prior to enrollment in the&#xD;
             study, and have no plans to move in the next three months.&#xD;
&#xD;
          -  The pregnancy test for females at intake must be negative. Additionally, women of&#xD;
             childbearing potential must be using an acceptable form of contraception. These&#xD;
             include: oral contraceptives, hormonal (levonorgestrel) or surgical implants, or&#xD;
             barrier plus spermicide.&#xD;
&#xD;
          -  Literate in English and able to read, understand, and complete the ratings scales and&#xD;
             questionnaires accurately, follow instructions, and make use of the behavioral&#xD;
             treatments.&#xD;
&#xD;
          -  Answer an advertisement in the newspaper/radio/television, or be referred from a&#xD;
             health care professional and express a wish to stop drinking.&#xD;
&#xD;
          -  Willingness to participate in behavioral treatments for alcoholism.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any current axis I DSM IV psychiatric disorder other than alcohol or nicotine&#xD;
             dependence&#xD;
&#xD;
          -  Elevation of liver enzymes - (SGOT), serum glutamic pyruvic transaminase (SGPT), blood&#xD;
             urea nitrogen (BUN), or lactate dehydrogenase (LDH) greater than four times the normal&#xD;
             range, or clinically significant elevated direct bilirubin as deemed by the principal&#xD;
             investigator.&#xD;
&#xD;
          -  Severe alcohol withdrawal symptoms which in the physicians opinion requires inpatient&#xD;
             treatment.&#xD;
&#xD;
          -  Serious medical co-morbidity requiring medical intervention or close supervision, or&#xD;
             any condition which can interfere with the receipt of ondansetron.&#xD;
&#xD;
          -  Severe or life-threatening adverse reactions to medications in the past or during this&#xD;
             clinical trial.&#xD;
&#xD;
          -  Female patients who are pregnant, lactating, or not adhering to an acceptable form of&#xD;
             contraception at any time during the study.&#xD;
&#xD;
          -  Received inpatient or outpatient treatment for alcohol dependence within the last 30&#xD;
             days (support groups such as AA are not exclusionary).&#xD;
&#xD;
          -  Compelled to participate in an alcohol treatment program to maintain their liberty.&#xD;
&#xD;
          -  Members of the same household.&#xD;
&#xD;
          -  Concurrent treatment with any medications having a potential effect on alcohol&#xD;
             consumption and related behaviors, or mood. These include: opiate antagonist (e.g.&#xD;
             naltrexone), glutamate antagonists (e.g., acamprosate), serotonin re-uptake inhibitors&#xD;
             (e.g. fluoxetine), serotonin antagonists (e.g. ritanserin or buspirone), other&#xD;
             antidepressants (e.g. tricylic antidepressants or monoamine oxidase inhibitors),&#xD;
             dopamine antagonists (e.g. haloperidol), calcium channel antagonists (e.g.&#xD;
             isradipine), or compounds with actions similar to disulfiram (antabuse) or nicotine.&#xD;
&#xD;
          -  Before double-blind randomization, urine must be free of opiates, cocaine,&#xD;
             amphetamines, barbiturates, benzodiazepines, prescription and non-prescription drugs.&#xD;
&#xD;
          -  Pyrexia of unknown origin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bankole Johnson, DSc,MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UVA CARE</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UVA CARE Richmond</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>October 6, 2008</study_first_submitted>
  <study_first_submitted_qc>October 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2008</study_first_posted>
  <last_update_submitted>March 14, 2013</last_update_submitted>
  <last_update_submitted_qc>March 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Bankole Johnson</investigator_full_name>
    <investigator_title>Chair of Psychiatry and NB Sciences</investigator_title>
  </responsible_party>
  <keyword>Alcohol</keyword>
  <keyword>Alcohol Dependence</keyword>
  <keyword>Alcoholism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

